| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alessandra Faggion Mocellin, Clara de Oliveira Lapa, Clarissa Severino Gam. A rare event of late agranulocytosis during clozapine use in schizophrenia and the importance of monitoring vitamin B12 levels in patients with severe psychiatric conditions: a case report. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2024-11-17. PMID:39550771. |
a rare event of late agranulocytosis during clozapine use in schizophrenia and the importance of monitoring vitamin b12 levels in patients with severe psychiatric conditions: a case report. |
2024-11-17 |
2024-11-22 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. Corrigendum to "The effect of clozapine on immune-related biomarkers in schizophrenia patients" [Brain Res. Bull. 218 (2024) 111104]. Brain research bulletin. 2024-11-17. PMID:39551651. |
corrigendum to "the effect of clozapine on immune-related biomarkers in schizophrenia patients" [brain res. |
2024-11-17 |
2024-11-22 |
Not clear |
| Paul O'Connell, Mohamed Alsaffa. The Treatment of Iatrogenic Anorgasmia in a Male Patient on Clozapine for Treatment-Resistant Schizophrenia: The Role of Pseudoephedrine. Journal of clinical psychopharmacology. 2024-11-11. PMID:39527675. |
the treatment of iatrogenic anorgasmia in a male patient on clozapine for treatment-resistant schizophrenia: the role of pseudoephedrine. |
2024-11-11 |
2024-11-17 |
Not clear |
| Adam Wysokiński, Joanna Dreczk. Clozapine Toxicity Predictor: Deep neural network model predicting clozapine toxicity and its therapeutic dose range. Psychiatry research. vol 342. 2024-11-10. PMID:39522262. |
clozapine is the gold standard for treatment-resistant schizophrenia; however, its superior efficacy is accompanied by potentially serious adverse events (neutropenia, seizures, constipations, pneumonia), many of which are also concentration-dependent. |
2024-11-10 |
2024-11-17 |
Not clear |
| Matthew B Bulkley, Kendahl Oberdorfer, Renee R Maa. A Case of Clozapine-Induced Hepatotoxicity: Management Considerations and Future Direction. Cureus. vol 16. issue 10. 2024-11-04. PMID:39493089. |
clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia. |
2024-11-04 |
2024-11-06 |
Not clear |
| Clélia Quiles, Jacques Taillard, Régis Lopez, Pierre Alexis Geoffroy, Francesco Salvo, Jean-Arthur Micoulaud-Franch. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review. Journal of sleep research. 2024-10-31. PMID:39478127. |
clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review. |
2024-10-31 |
2024-11-02 |
Not clear |
| Clélia Quiles, Jacques Taillard, Régis Lopez, Pierre Alexis Geoffroy, Francesco Salvo, Jean-Arthur Micoulaud-Franch. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review. Journal of sleep research. 2024-10-31. PMID:39478127. |
clozapine is effective in treatment-resistant schizophrenia but with adverse effects including sedation. |
2024-10-31 |
2024-11-02 |
Not clear |
| Clélia Quiles, Jacques Taillard, Régis Lopez, Pierre Alexis Geoffroy, Francesco Salvo, Jean-Arthur Micoulaud-Franch. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review. Journal of sleep research. 2024-10-31. PMID:39478127. |
the aim of this systematic review was to synthesise the literature evaluating the impact of clozapine on the objective assessment of hypersomnolence in people with schizophrenia. |
2024-10-31 |
2024-11-02 |
Not clear |
| Michael A Cummings, Ai-Li W Arias, Stephen M Stah. What is the neurobiology of schizophrenia? CNS spectrums. 2024-10-30. PMID:39473188. |
clozapine remains the "gold standard" in managing treatment-resistant schizophrenia. |
2024-10-30 |
2024-11-02 |
Not clear |
| Bethany Yeise. Evidence-based treatment for schizophrenia: a personal perspective. CNS spectrums. 2024-10-28. PMID:39463127. |
my schizophrenia has been in full remission since 2008, thanks to treatment with clozapine, the vastly underutilized medication for refractory schizophrenia. |
2024-10-28 |
2024-10-30 |
Not clear |
| Marwa H Abdallah, Mona M Shahien, Hemat El-Sayed El-Horany, Enas Haridy Ahmed, Hanan M El-Nahas, Nourhan A Abdulla, Tarek M Ibrahi. Evaluation of Mucoadhesive Nano-Bilosomal In Situ Gels Containing Anti-Psychotic Clozapine for Treatment of Schizophrenia: In Vitro and In Vivo Studies. Pharmaceuticals (Basel, Switzerland). vol 17. issue 10. 2024-10-26. PMID:39459043. |
evaluation of mucoadhesive nano-bilosomal in situ gels containing anti-psychotic clozapine for treatment of schizophrenia: in vitro and in vivo studies. |
2024-10-26 |
2024-10-29 |
Not clear |
| Sung Woo Joo, Sang Kyoung Kim, Won Hee Lee, Se Hyun Kim, Jungsun Le. Association of clozapine with structural and resting-state functional abnormalities of the hippocampus in chronic schizophrenia. Frontiers in psychiatry. vol 15. 2024-10-21. PMID:39429532. |
association of clozapine with structural and resting-state functional abnormalities of the hippocampus in chronic schizophrenia. |
2024-10-21 |
2024-10-23 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
the effect of clozapine on immune-related biomarkers in schizophrenia patients. |
2024-10-18 |
2024-10-21 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
clozapine is the gold standard for therapy-resistant schizophrenia (trs), yet it has limited effectiveness and serious adverse events in some patients. |
2024-10-18 |
2024-10-21 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
previous investigations have demonstrated the immune system alteration after clozapine treatment in schizophrenia patients. |
2024-10-18 |
2024-10-21 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
besides, it has been proposed that clozapine changes the cytokines profile in schizophrenia patients. |
2024-10-18 |
2024-10-21 |
Not clear |
| Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Li. The effect of clozapine on immune-related biomarkers in schizophrenia patients. Brain research bulletin. 2024-10-18. PMID:39424000. |
therefore, this study aimed to comprehensively review the effect of clozapine on immune-related biomarkers in schizophrenia patients. |
2024-10-18 |
2024-10-21 |
Not clear |
| Dan Siskind, Claudia Bull, Shuichi Suetani, Nicola Warren, Anastasia Suraev, Iain McGregor, Steve Kisely, Veronica De Monte, Mike Trott, Manju Shine, Vikas Moudgil, Gail Robinson, Stephen Parker, Ravikumar Krishnaiah, Terry Stedman, Allan Drummond, Sarah Medland, Ravi Iyer, Andrea Bake. Protocol for Cancloz: multicentre randomised, placebo-controlled, double-blind, parallel-group adaptive trial of cannabidiol for clozapine-resistant schizophrenia. BJPsych open. vol 10. issue 5. 2024-10-03. PMID:39359160. |
although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia (trs), only 40% of people with trs respond, and there is limited evidence for augmentation agents. |
2024-10-03 |
2024-10-05 |
Not clear |
| Emilio Fernandez-Egea, Robert A McCutcheo. Clozapine monitoring requirements: is it time for an update? The British journal of psychiatry : the journal of mental science. 2024-10-03. PMID:39359180. |
their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. |
2024-10-03 |
2024-10-05 |
Not clear |
| Amy L Gillespie, Emma M Walker, Eilis Hannon, Grant A McQueen, Kyra-Verena Sendt, Alessia Avila, John Lally, Cynthia Okhuijsen-Pfeifer, Marte van der Horst, Alkomiet Hasan, Emma L Dempster, Joe Burrage, Jan Bogers, Dan Cohen, Marco P Boks, David A Collier, Alice Egerton, Jurjen J Luykx, Jonathan Mill, James H MacCab. Longitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts. Translational psychiatry. vol 14. issue 1. 2024-09-28. PMID:39333502. |
longitudinal changes in dna methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts. |
2024-09-28 |
2024-10-01 |
Not clear |